---
title: "Deutetrabenazine - Tardive Dyskinesia"
sidebar: mydoc_sidebar
permalink: db12161-mesh-d000071057-1.html
toc: false 
---


Path ID: `DB12161_MESH_D000071057_1`
{% include image.html url="images/db12161-mesh-d000071057-1.png" file="db12161-mesh-d000071057-1.png" alt="db12161-mesh-d000071057-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/DB:DB04844">DB:DB04844 </a> | Tetrabenazine | Drug |
| <a href="https://identifiers.org/MESH:C000609690">MESH:C000609690 </a> | Deutetrabenazine | Drug |
| <a href="https://identifiers.org/UniProt:Q05940">UniProt:Q05940 </a> | Synaptic vesicular amine transporter | Protein |
| <a href="https://identifiers.org/GO:0015842">GO:0015842 </a> | Aminergic neurotransmitter loading into synaptic vesicle | BiologicalProcess |
| <a href="https://identifiers.org/GO:0042420">GO:0042420 </a> | Dopamine catabolic process | BiologicalProcess |
| <a href="https://identifiers.org/GO:0061527">GO:0061527 </a> | Dopamine secretion, neurotransmission | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D000071057">MESH:D000071057 </a> | Tardive dyskinesia | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Deutetrabenazine | HAS METABOLITE | Tetrabenazine |
| Tetrabenazine | DECREASES ACTIVITY OF | Synaptic Vesicular Amine Transporter |
| Synaptic Vesicular Amine Transporter | POSITIVELY REGULATES | Aminergic Neurotransmitter Loading Into Synaptic Vesicle |
| Aminergic Neurotransmitter Loading Into Synaptic Vesicle | PREVENTS | Dopamine Catabolic Process |
| Dopamine Catabolic Process | NEGATIVELY REGULATES | Dopamine Secretion, Neurotransmission |
| Dopamine Secretion, Neurotransmission | CORRELATED WITH | Tardive Dyskinesia |
|---------|-----------|---------|

Comment: The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound.

Reference: 
  - [https://go.drugbank.com/drugs/DB12161](https://go.drugbank.com/drugs/DB12161)
  - [https://en.wikipedia.org/wiki/Tardive_dyskinesia](https://en.wikipedia.org/wiki/Tardive_dyskinesia)
  - [https://en.wikipedia.org/wiki/Tetrabenazine#Pharmacology](https://en.wikipedia.org/wiki/Tetrabenazine#Pharmacology)
